Zimbabwe is initiating an urgent transition to safeguard critical HIV services, including the procurement and distribution of antiretroviral drugs (ARVs), following the cessation of United States-funded health programmes this week. The US Embassy in Harare announced last week that Washington would discontinue all funding for Zimbabwe’s health initiatives by the end of September, after negotiations for a proposed US$367 million funding deal collapsed.
Zimbabwean officials cited concerns over national sovereignty and data privacy as reasons for rejecting the deal, specifically Washington’s demands for access to biological samples for research and commercial purposes without reciprocal benefit-sharing. The National AIDS Council (NAC) has convened implementing partners to identify essential programmes that must now be absorbed into the national response, prioritising interventions directly affecting patients’ access to treatment.
Key Players Involved
- United States Government: Discontinued US$367 million health funding to Zimbabwe.
- Zimbabwean Government: Rejected funding deal citing sovereignty and data privacy concerns.
- National AIDS Council (NAC): Coordinating efforts to mitigate impact and ensure continuity of HIV services.
Event Timeline
- Last Week (approx. Sep 19-25, 2026): US Embassy in Harare announced the discontinuation of health funding.
- September 26, 2026: News reports confirm the halt in US funding and Zimbabwe’s efforts to transition services.
- This Week (Sep 22-28, 2026): US-funded health programmes officially wind down.
